225 related articles for article (PubMed ID: 11740049)
1. Inactivation of the p16 gene in human pituitary nonfunctioning tumors by hypermethylation is more common in null cell adenomas.
Ruebel KH; Jin L; Zhang S; Scheithauer BW; Lloyd RV
Endocr Pathol; 2001; 12(3):281-9. PubMed ID: 11740049
[TBL] [Abstract][Full Text] [Related]
2. CDKN2A/p16 inactivation is related to pituitary adenoma type and size.
Seemann N; Kuhn D; Wrocklage C; Keyvani K; Hackl W; Buchfelder M; Fahlbusch R; Paulus W
J Pathol; 2001 Apr; 193(4):491-7. PubMed ID: 11276008
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas.
Simpson DJ; Bicknell JE; McNicol AM; Clayton RN; Farrell WE
Genes Chromosomes Cancer; 1999 Apr; 24(4):328-36. PubMed ID: 10092131
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathology shows p16 methylation in nonadenomatous pituitaries from patients with Cushing's disease.
Simpson DJ; McNicol AM; Murray DC; Bahar A; Turner HE; Wass JA; Esiri MM; Clayton RN; Farrell WE
Clin Cancer Res; 2004 Mar; 10(5):1780-8. PubMed ID: 15014032
[TBL] [Abstract][Full Text] [Related]
5. The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas.
Ogino A; Yoshino A; Katayama Y; Watanabe T; Ota T; Komine C; Yokoyama T; Fukushima T
J Neuropathol Exp Neurol; 2005 May; 64(5):398-403. PubMed ID: 15892297
[TBL] [Abstract][Full Text] [Related]
6. Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas.
Gejman R; Batista DL; Zhong Y; Zhou Y; Zhang X; Swearingen B; Stratakis CA; Hedley-Whyte ET; Klibanski A
J Clin Endocrinol Metab; 2008 Oct; 93(10):4119-25. PubMed ID: 18628527
[TBL] [Abstract][Full Text] [Related]
7. Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation.
Woloschak M; Yu A; Post KD
Mol Carcinog; 1997 Aug; 19(4):221-4. PubMed ID: 9290697
[TBL] [Abstract][Full Text] [Related]
8. p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumours.
Jaffrain-Rea ML; Ferretti E; Toniato E; Cannita K; Santoro A; Di Stefano D; Ricevuto E; Maroder M; Tamburrano G; Cantore G; Gulino A; Martinotti S
Clin Endocrinol (Oxf); 1999 Sep; 51(3):317-25. PubMed ID: 10469011
[TBL] [Abstract][Full Text] [Related]
9. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.
Kirsch M; Mörz M; Pinzer T; Schackert HK; Schackert G
Genes Chromosomes Cancer; 2009 Feb; 48(2):143-54. PubMed ID: 18973139
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas.
Yoshino A; Katayama Y; Ogino A; Watanabe T; Yachi K; Ohta T; Komine C; Yokoyama T; Fukushima T
J Neurooncol; 2007 Jun; 83(2):153-62. PubMed ID: 17216555
[TBL] [Abstract][Full Text] [Related]
11. Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma.
Revill K; Dudley KJ; Clayton RN; McNicol AM; Farrell WE
Endocr Relat Cancer; 2009 Jun; 16(2):537-48. PubMed ID: 19218280
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of DNA (Cytosine-5)-Methyltransferase 1 (DNMT1) And DNA (Cytosine-5)-Methyltransferase 3A (DNMT3A) Is Associated with Aggressive Behavior and Hypermethylation of Tumor Suppressor Genes in Human Pituitary Adenomas.
Ma HS; Wang EL; Xu WF; Yamada S; Yoshimoto K; Qian ZR; Shi L; Liu LL; Li XH
Med Sci Monit; 2018 Jul; 24():4841-4850. PubMed ID: 30002361
[TBL] [Abstract][Full Text] [Related]
13. P16 overexpression in pituitary adenomas studied by immunohistochemistry and in situ hybridization.
Yi J; Yu D; Chen Y; Xiong W; Li X; Shen J; Tang X
Chin Med J (Engl); 2000 Feb; 113(2):162-6. PubMed ID: 11775544
[TBL] [Abstract][Full Text] [Related]
14. Identification of a subtype-specific ENC1 gene related to invasiveness in human pituitary null cell adenoma and oncocytomas.
Feng J; Hong L; Wu Y; Li C; Wan H; Li G; Sun Y; Yu S; Chittiboina P; Montgomery B; Zhuang Z; Zhang Y
J Neurooncol; 2014 Sep; 119(2):307-15. PubMed ID: 24916845
[TBL] [Abstract][Full Text] [Related]
15. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation.
Muscarella P; Melvin WS; Fisher WE; Foor J; Ellison EC; Herman JG; Schirmer WJ; Hitchcock CL; DeYoung BR; Weghorst CM
Cancer Res; 1998 Jan; 58(2):237-40. PubMed ID: 9443399
[TBL] [Abstract][Full Text] [Related]
16. Expression of FOXL2 in human normal pituitaries and pituitary adenomas.
Egashira N; Takekoshi S; Takei M; Teramoto A; Osamura RY
Mod Pathol; 2011 Jun; 24(6):765-73. PubMed ID: 21478824
[TBL] [Abstract][Full Text] [Related]
17. Expression of neuro D1 in human normal pituitaries and pituitary adenomas.
Oyama K; Sanno N; Teramoto A; Osamura RY
Mod Pathol; 2001 Sep; 14(9):892-9. PubMed ID: 11557786
[TBL] [Abstract][Full Text] [Related]
18. Reduction of GSTP1 expression by DNA methylation correlates with clinicopathological features in pituitary adenomas.
Yuan Y; Qian ZR; Sano T; Asa SL; Yamada S; Kagawa N; Kudo E
Mod Pathol; 2008 Jul; 21(7):856-65. PubMed ID: 18425080
[TBL] [Abstract][Full Text] [Related]
19. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
20. Cell-specific expression of estrogen receptor in the human pituitary and its adenomas.
Zafar M; Ezzat S; Ramyar L; Pan N; Smyth HS; Asa SL
J Clin Endocrinol Metab; 1995 Dec; 80(12):3621-7. PubMed ID: 8530610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
